Market Introduction
Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.
Thus, the growing approvals for cell therapies is expected to create a significant demand for cell therapy bioprocessing in the coming years, which is further anticipated to drive the cell therapy bioprocessing market.
Countries such as UAE, and Saudi Arabia have also registered a significant number of positive patients. This region is developing in terms of the medical industry. The countries in this region are highly dependent on medical devices and pharmaceutical products. Therefore, countries have faced several challenges for their requirements. Initial phase of lockdown in various countries has affected the supply of many bioprocessing in these regions. However, the lockdown has affected the supply chain of various companies in these regions. Therefore, many organizations are collaborating with others to overcome this pandemic by using cell therapies for the treatment of COVID 19. For instance, in May 2020, Prince of Abu Dhabi has announced to cover all costs of Stem cell therapy of COVID 19 patients. Moreover, United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC) has entered into collaboration agreement with Pluristem Therapeutics Inc. to develop cell therapies and regenerative medicines for the treatment of COVID-19. This cell therapy has been named UAECell19, which has been used to treat approximately 5000 COVID-19 affected people successfully. Such initiatives will bring significant growth for cell therapy market in long run.
Market Overview and Dynamics
The Cell therapy bioprocessing market in Middle East and Africa is expected to grow from US$ 393.7 million in 2021 to US$ 832.5 million by 2028; it is estimated to grow at a CAGR of 11.3% from 2021 to 2028. In the last few years, there has been significant investments done by the biopharmaceutical companies in the cell and gene therapy segment. According to the Alliance for Regenerative Medicine (ARM), investments in the cell and gene therapy has doubled in 2020 compared to 2019 and considerably higher than 2018. Companies across the world have invested US$ 19.9 billion in 2020, whereas the investments were accounted for US$ 13.5 billion in 2018 and US$ 9.8 billion in 2019. Thus, owing to the heavy investments, the market is expected to be flourishing in the coming years.
Key Market Segments
In terms of technology, the bioreactors segment accounted for the largest share of the Middle East and Africa cell therapy bioprocessing market in 2020. In terms of cell type, the stem cell segment accounted for the largest share of the Middle East and Africa cell therapy bioprocessing market in 2020. In terms of indication, the oncology segment accounted for the largest share of the Middle East and Africa cell therapy bioprocessing market in 2020. In terms of end user, the academic and research institute segment held a larger market share of the cell therapy bioprocessing market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Cell therapy bioprocessing market in Middle East and Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc.
Reasons to buy report
MIDDLE EAST AND AFRICA CELL THERAPY BIOPROCESSING MARKET SEGMENTATION
By Technology
By Cell Type
By Indication
By End User
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 393.7 Million |
| Market Size by 2028 | US$ 832.5 Million |
| CAGR (2021 - 2028) | 11.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East and Africa Cell Therapy Bioprocessing Market is valued at US$ 393.7 Million in 2021, it is projected to reach US$ 832.5 Million by 2028.
As per our report Middle East and Africa Cell Therapy Bioprocessing Market, the market size is valued at US$ 393.7 Million in 2021, projecting it to reach US$ 832.5 Million by 2028. This translates to a CAGR of approximately 11.3% during the forecast period.
The Middle East and Africa Cell Therapy Bioprocessing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Cell Therapy Bioprocessing Market report:
The Middle East and Africa Cell Therapy Bioprocessing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Cell Therapy Bioprocessing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Cell Therapy Bioprocessing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East and Africa Cell Therapy Bioprocessing Market
